Treatment of Induced Mesenchymal Stem Cells in Ischemic Heart Diseases: Hypoxia

Abstract

When traditional methods fall short in treating ischemic heart diseases caused by reduced blood flow to the heart due to narrowed coronary arteries, alternative solutions such as cellular therapies are thought. Mesenchymal stem cells (MSCs) are advantageous due to their ease of isolation, migration, and immunomodulatory properties. Preconditioning, which involves regulating cell functions through external stimuli, enhances the effectiveness of cellular therapy. Hypoxia, known as oxygen deprivation, is known to regulate cell survival, migration, and differentiation capabilities. This review explores the current state and future of hypoxia preconditioning in enhancing the therapeutic effects of stem cells.

Keywords

• Mesenchymal stem cells
• ischemic heart diseases
• preconditioning
• hypoxia

References

1. I.o. Medicine, Cardiovascular disability: Updating the social security listings, The National Academies Press, Washington, DC, 2010.
2. L.M. Buja, The pathobiology of acute coronary syndromes: Clinical implications and central role of the mitochondria, Texas Heart Institute journal, 40 (2013) 221–228.
3. L.M. Buja, R.S. Vander Heide, Pathobiology of ischemic heart disease: Past, present and future, Cardiovasc Pathol, 25 (2016) 214-220.
4. E. Falk, Pathogenesis of atherosclerosis, J Am Coll Cardiol, 47 (2006) 7-12.
5. R.V. Jensen, M.V. Hjortbak, H.E. Botker, Ischemic heart disease: An update, Semin Nucl Med, 50 (2020) 195-207.
6. E.J. Benjamin, P. Muntner, A. Alonso, M.S. Bittencourt, C.W. Callaway, A.P. Carson, A.M. Chamberlain, A.R. Chang, S. Cheng, S.R. Das, F.N. Delling, L. Djousse, M.S.V. Elkind, J.F. Ferguson, M. Fornage, L.C. Jordan, S.S. Khan, B.M. Kissela, K.L. Knutson, . . . S.S. Virani, Heart disease and stroke statistics—2019 update: A report from the american heart association, Circulation, 139 (2019) 56-528.
7. E. Braunwald, Heart failure, JACC Heart Fail, 1 (2013) 1-20.
8. N. Townsend, L. Wilson, P. Bhatnagar, K. Wickramasinghe, M. Rayner, M. Nichols, Cardiovascular disease in europe: Epidemiological update 2016, Eur Heart J, 37 (2016) 3232-3245.

9. C.K. Chow, S. Jolly, P. Rao-Melacini, K.A. Fox, S.S. Anand, S. Yusuf, Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes, Circulation, 121 (2010) 750-758.
10. A. Ruusalepp, G. Czibik, T. Flatebo, J. Vaage, G. Valen, Myocardial protection evoked by hyperoxic exposure involves signaling through nitric oxide and mitogen activated protein kinases, Basic Res Cardiol, 102 (2007) 318-326.
11. M.R. Costanzo, S. Augustine, R. Bourge, M. Bristow, J.B. O’Connell, D. Driscoll, E. Rose, Selection and treatment of candidates for heart transplantation, Circulation, 92 (1995) 3593–3612.
12. D.R. Holmes, Jr., M.B. Leon, J.W. Moses, J.J. Popma, D. Cutlip, P.J. Fitzgerald, C. Brown, T. Fischell, S.C. Wong, M. Midei, D. Snead, R.E. Kuntz, Analysis of 1-year clinical outcomes in the sirius trial: A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis, Circulation, 109 (2004) 634-640.
13. D. Choi, K.C. Hwang, K.Y. Lee, Y.H. Kim, Ischemic heart diseases: Current treatments and future, J Control Release, 140 (2009) 194-202.
14. M.T. Alrefai, D. Murali, A. Paul, K.M. Ridwan, J.M. Connell, D. Shum-Tim, Cardiac tissue engineering and regeneration using cell-based therapy, Stem Cells Cloning, 8 (2015) 81-101.
15. H.C. Ott, T.S. Matthiesen, S.K. Goh, L.D. Black, S.M. Kren, T.I. Netoff, D.A. Taylor, Perfusion-decellularized matrix: Using nature's platform to engineer a bioartificial heart, Nat Med, 14 (2008) 213-221.
16. N.K. Paschos, W.E. Brown, R. Eswaramoorthy, J.C. Hu, K.A. Athanasiou, Advances in tissue engineering through stem cell-based co-culture, J Tissue Eng Regen Med, 9 (2015) 488-503.
17. H. Peng, A. Abdel-Latif, Cellular therapy for ischemic heart disease: An update, 10, Stem cells, Springer, Cham, 2019, 195–213.
18. H. Yu, K. Lu, J. Zhu, J. Wang, Stem cell therapy for ischemic heart diseases, Br Med Bull, 121 (2017) 135-154.
19. R. Bhatheja, D. Mukherjee, Acute coronary syndromes: Unstable angina/non-st elevation myocardial infarction, Crit Care Clin, 23 (2007) 709-735.
20. E. Van Belle, K. Abolmaali, C. Bauters, E.P. McFadden, J.M. Lablanche, M.E. Bertrand, Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients, J Am Coll Cardiol, 34 (1999) 476-485.
21. J.B. Shea, W.H. Maisel, Cardiology patient pages. Cardioversion, Circulation, 106 (2002) 176-178.
22. Y.M. Yang, I. Moussa, Percutaneous coronary intervention and drug-eluting stents, CMAJ, 172 (2005) 323-325.
23. J.P. Glotzbach, V.W. Wong, G.C. Gurtner, M.T. Longaker, Regenerative medicine, Curr Probl Surg, 48 (2011) 148-212.
24. H.R. Schöler, The potential of stem cells: An inventory, Humanbiotechnology as social challenge, Ashgate Publishing, London, 2007.
25. J. Gopalarethinam, A.P. Nair, M. Iyer, B. Vellingiri, M.D. Subramaniam, Advantages of mesenchymal stem cell over the other stem cells, Acta Histochem, 125 (2023) 152041.
26. B. Arjmand, M. Abedi, M. Arabi, S. Alavi-Moghadam, M. Rezaei-Tavirani, M. Hadavandkhani, A. Tayanloo-Beik, R. Kordi, P.P. Roudsari, B. Larijani, Regenerative medicine for the treatment of ischemic heart disease; status and future perspectives, Front Cell Dev Biol, 9 (2021)
27. S.A. Fisher, C. Doree, A. Mathur, D.P. Taggart, E. Martin-Rendon, Stem cell therapy for chronic ischaemic heart disease and congestive heart failure, Cochrane Database Syst Rev, 12 (2016)
28. D. Orlic, J. Kajstura, S. Chimenti, Bone marrow cells regenerate infarcted myocardium, Nature, 410 (2001) 701–705.
29. C. Dall, M. Khan, C.A. Chen, M.G. Angelos, Oxygen cycling to improve survival of stem cells for myocardial repair: A review, Life Sci, 153 (2016) 124-131.
30. R.Z. Shi, Q.P. Li, Improving outcome of transplanted mesenchymal stem cells for ischemic heart disease, Biochem Biophys Res Commun, 376 (2008) 247-250.
31. T. Asahara, A. Kawamoto, Endothelial progenitor cells for postnatal vasculogenesis, American journal of physiology, Cell physiology, 287 (2004) 572-579.
32. C. Valina, K. Pinkernell, Y.H. Song, X. Bai, S. Sadat, R.J. Campeau, T.H. Le Jemtel, E. Alt, Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction, Eur Heart J, 28 (2007) 2667-2677.
33. L. Wang, J. Deng, W. Tian, B. Xiang, T. Yang, G. Li, J. Wang, M. Gruwel, T. Kashour, J. Rendell, M. Glogowski, B. Tomanek, D. Freed, R. Deslauriers, R.C. Arora, G. Tian, Adipose-derived stem cells are an effective cell candidate for treatment of heart failure: An mr imaging study of rat hearts, Am J Physiol Heart Circ Physiol, 297 (2009) 1020-1031.
34. R.E. Michler, The current status of stem cell therapy in ischemic heart disease, J Card Surg, 33 (2018) 520-531.
35. Y. Oike, Y. Ito, H. Maekawa, T. Morisada, Y. Kubota, M. Akao, T. Urano, K. Yasunaga, T. Suda, Angiopoietin-related growth factor (agf) promotes angiogenesis, Blood, 103 (2004) 3760-3765.
36. B. Abd Emami, E. Mahmoudi, M.A. Shokrgozar, M.M. Dehghan, S. Farzad Mohajeri, N. Haghighipour, S.H. Marjanmehr, M. Molazem, S. Amin, H. Gholami, Mechanical and chemical predifferentiation of mesenchymal stem cells into cardiomyocytes and their effectiveness on acute myocardial infarction, Artif Organs, 42 (2018) 114-126.
37. M. Lin, X. Liu, H. Zheng, X. Huang, Y. Wu, A. Huang, H. Zhu, Y. Hu, W. Mai, Y. Huang, Igf-1 enhances bmsc viability, migration, and anti-apoptosis in myocardial infarction via secreted frizzled-related protein 2 pathway, Stem cell research & therapy, 11 (2020)
38. D. Lu, Y. Liao, S.H. Zhu, Q.C. Chen, D.M. Xie, J.J. Liao, X. Feng, M.H. Jiang, W. He, Bone-derived nestin-positive mesenchymal stem cells improve cardiac function via recruiting cardiac endothelial cells after myocardial infarction, Stem Cell Res Ther, 10 (2019)
39. H. Sadraddin, R. Gaebel, A. Skorska, C.A. Lux, S. Sasse, B. Ahmad, P. Vasudevan, G. Steinhoff, R. David, Cd271(+) human mesenchymal stem cells show antiarrhythmic effects in a novel murine infarction model, Cells, 8 (2019)
40. Y. Tu, Y. Qiu, L. Liu, T. Huang, H. Tang, Y. Liu, W. Guo, H. Jiang, Y. Fan, B. Yu, Mi r -15a/15b cluster modulates survival of mesenchymal stem cells to improve its therapeutic efficacy of myocardial infarction, J Am Heart Assoc, 8 (2019)
41. Z. Zhang, Y. Tan, L. Zhu, B. Zhang, P. Feng, E. Gao, C. Xu, X. Wang, W. Yi, Y. Sun, Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated erk1/2-sod2 pathway, Life Sci, 231 (2019)
42. S. Golpanian, A. Wolf, K.E. Hatzistergos, J.M. Hare, Rebuilding the damaged heart: Mesenchymal stem cells, cell-based therapy, and engineered heart tissue, Physiol Rev, 96 (2016) 1127-1168.
43. A.O. Fakoya, New delivery systems of stem cells for vascular regeneration in ischemia, Front Cardiovasc Med, 4 (2017)
44. S. Tomita, R.K. Li, R.D. Weisel, D.A. Mickle, E.J. Kim, T. Sakai, Z.Q. Jia, Autologous transplantation of bone marrow cells improves damaged heart function, Circulation, 100 (1999) 247–256.
45. J.L. Chan, J.G. Miller, Y. Zhou, P.G. Robey, D.F. Stroncek, A.E. Arai, V. Sachdev, K.A. Horvath, Intramyocardial bone marrow stem cells in patients undergoing cardiac surgical revascularization, Ann Thorac Surg, 109 (2020) 1142-1149.
46. A. Varbo, M. Benn, A. Tybjaerg-Hansen, B.G. Nordestgaard, Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation, Circulation, 128 (2013) 1298-1309.
47. J.M. Hare, J.E. Fishman, G. Gerstenblith, D.L. DiFede Velazquez, J.P. Zambrano, V.Y. Suncion, M. Tracy, E. Ghersin, P.V. Johnston, J.A. Brinker, E. Breton, J. Davis-Sproul, I.H. Schulman, J. Byrnes, A.M. Mendizabal, M.H. Lowery, D. Rouy, P. Altman, C. Wong Po Foo, . . . A. Lardo, Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The poseidon randomized trial, JAMA, 308 (2012) 2369-2379.
48. V. Karantalis, D.L. DiFede, G. Gerstenblith, S. Pham, J. Symes, J.P. Zambrano, J. Fishman, P. Pattany, I. McNiece, J. Conte, S. Schulman, K. Wu, A. Shah, E. Breton, J. Davis-Sproul, R. Schwarz, G. Feigenbaum, M. Mushtaq, V.Y. Suncion, . . . J.M. Hare, Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The prospective randomized study of mesenchymal stem cell therapy in patients undergoing cardiac surgery (prometheus) trial, Circ Res, 114 (2014) 1302-1310.
49. R. Bolli, R.D. Mitrani, J.M. Hare, C.J. Pepine, E.C. Perin, J.T. Willerson, J.H. Traverse, T.D. Henry, P.C. Yang, M.P. Murphy, K.L. March, I.H. Schulman, S. Ikram, D.P. Lee, C. O'Brien, J.A. Lima, M.R. Ostovaneh, B. Ambale-Venkatesh, G. Lewis, . . . N. Cardiovascular Cell Therapy Research, A phase ii study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: The cctrn concert-hf trial, Eur J Heart Fail, 23 (2021) 661-674.
50. C.D. Correia, A. Ferreira, M.T. Fernandes, B.M. Silva, F. Esteves, H.S. Leitao, J. Braganca, S.M. Calado, Human stem cells for cardiac disease modeling and preclinical and clinical applications-are we on the road to success?, Cells, 12 (2023)
51. A.J. Kanelidis, C. Premer, J. Lopez, W. Balkan, J.M. Hare, Route of delivery modulates the efficacy of mesenchymal stem cell therapy for myocardial infarction: A meta-analysis of preclinical studies and clinical trials, Circ Res, 120 (2017) 1139-1150.
52. V. Florea, A.C. Rieger, D.L. DiFede, J. El-Khorazaty, M. Natsumeda, M.N. Banerjee, B.A. Tompkins, A. Khan, I.H. Schulman, A.M. Landin, M. Mushtaq, S. Golpanian, M.H. Lowery, J.J. Byrnes, R.C. Hendel, M.G. Cohen, K. Valasaki, M.V. Pujol, E. Ghersin, . . . J.M. Hare, Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (the trident study), Circ Res, 121 (2017) 1279-1290.
53. Y. Lv, C.W. Gao, B. Liu, H.Y. Wang, H.P. Wang, Bmp-2 combined with salvianolic acid b promotes cardiomyocyte differentiation of rat bone marrow mesenchymal stem cells, Kaohsiung J Med Sci, 33 (2017) 477-485.
54. T.C. Moloney, D.B. Hoban, F.P. Barry, L. Howard, E. Dowd, Kinetics of thermally induced heat shock protein 27 and 70 expression by bone marrow-derived mesenchymal stem cells, Protein Sci, 21 (2012) 904-909.
55. H. Wei, Z. Li, S. Hu, X. Chen, X. Cong, Apoptosis of mesenchymal stem cells induced by hydrogen peroxide concerns both endoplasmic reticulum stress and mitochondrial death pathway through regulation of caspases, p38 and jnk, J Cell Biochem, 111 (2010) 967-978.
56. D. Guzel, A.D. Dursun, H. Ficicilar, D. Tekin, A. Tanyeli, F. Akat, F. Topal Celikkan, B. Sabuncuoglu, M. Bastug, Effect of intermittent hypoxia on the cardiac hif-1/vegf pathway in experimental type 1 diabetes mellitus, Anatol J Cardiol, 16 (2016) 76-83.
57. K.A. Jackson, S.M. Majka, H. Wang, J. Pocius, C.J. Hartley, M.W. Majesky, M.L. Entman, L.H. Michael, K.K. Hirschi, M.A. Goodell, Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells, The Journal of clinical investigation, 107 (2001) 1395–1402.
58. B. Antebi, L.A. Rodriguez, 2nd, K.P. Walker, 3rd, A.M. Asher, R.M. Kamucheka, L. Alvarado, A. Mohammadipoor, L.C. Cancio, Short-term physiological hypoxia potentiates the therapeutic function of mesenchymal stem cells, Stem Cell Res Ther, 9 (2018)
59. N. Bigot, A. Mouche, M. Preti, S. Loisel, M.L. Renoud, R. Le Guevel, L. Sensebe, K. Tarte, R. Pedeux, Hypoxia differentially modulates the genomic stability of clinical-grade adscs and bm-mscs in long-term culture, Stem Cells, 33 (2015) 3608-3620.
60. V. Pulido-Escribano, B. Torrecillas-Baena, M. Camacho-Cardenosa, G. Dorado, M.A. Galvez-Moreno, A. Casado-Diaz, Role of hypoxia preconditioning in therapeutic potential of mesenchymal stem-cell-derived extracellular vesicles, World J Stem Cells, 14 (2022) 453-472.
61. S.M. Chacko, S. Ahmed, K. Selvendiran, M.L. Kuppusamy, M. Khan, P. Kuppusamy, Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells, Am J Physiol Cell Physiol, 299 (2010) C1562-1570.
62. X. Hu, S.P. Yu, J.L. Fraser, Z. Lu, M.E. Ogle, J.A. Wang, L. Wei, Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis, J Thorac Cardiovasc Surg, 135 (2008) 799-808.
63. S.L. Stubbs, S.T. Hsiao, H.M. Peshavariya, S.Y. Lim, G.J. Dusting, R.J. Dilley, Hypoxic preconditioning enhances survival of human adipose-derived stem cells and conditions endothelial cells in vitro, Stem Cells Dev, 21 (2012) 1887-1896.
64. S. Germain, X. Wang, C. Liu, S. Li, Y. Xu, P. Chen, Y. Liu, Q. Ding, W. Wahafu, B. Hong, M. Yang, Hypoxia precondition promotes adipose-derived mesenchymal stem cells based repair of diabetic erectile dysfunction via augmenting angiogenesis and neuroprotection, Plos One, 10 (2015)
65. J. Hou, L. Wang, H. Long, H. Wu, Q. Wu, T. Zhong, X. Chen, C. Zhou, T. Guo, T. Wang, Hypoxia preconditioning promotes cardiac stem cell survival and cardiogenic differentiation in vitro involving activation of the hif-1alpha/apelin/apj axis, Stem Cell Res Ther, 8 (2017)
66. J.S. Lee, J.C. Park, T.W. Kim, B.J. Jung, Y. Lee, E.K. Shim, S. Park, E.Y. Choi, K.S. Cho, C.S. Kim, Human bone marrow stem cells cultured under hypoxic conditions present altered characteristics and enhanced in vivo tissue regeneration, Bone, 78 (2015) 34-45.
67. N. Maulik, D.K. Das, Potentiation of angiogenic response by ischemic and hypoxic preconditioning of the heart, Journal of cellular and molecular medicine, 6 (2002) 13–24.
68. H. Sasaki, S. Fukuda, H. Otani, L. Zhu, G. Yamaura, R.M. Engelman, D.K. Das, N. Maulik, Hypoxic preconditioning triggers myocardial angiogenesis: A novel approach to enhance contractile functional reserve in rat with myocardial infarction, J Mol Cell Cardiol, 34 (2002) 335-348.
69. J.W. Choi, K.E. Kim, C.Y. Lee, J. Lee, H.H. Seo, K.H. Lim, E. Choi, S. Lim, S. Lee, S.W. Kim, K.C. Hwang, Alterations in cardiomyocyte differentiation-related proteins in rat mesenchymal stem cells exposed to hypoxia, Cell Physiol Biochem, 39 (2016) 1595-1607.
70. D. Tekin, A.D. Dursun, L. Xi, Hypoxia inducible factor 1 (hif-1) and cardioprotection, Acta Pharmacol Sin, 31 (2010) 1085-1094.
71. I. Cerrada, A. Ruiz-Sauri, R. Carrero, C. Trigueros, A. Dorronsoro, J.M. Sanchez-Puelles, A. Diez-Juan, J.A. Montero, P. Sepulveda, Hypoxia-inducible factor 1 alpha contributes to cardiac healing in mesenchymal stem cells-mediated cardiac repair, Stem Cells Dev, 22 (2013) 501-511.
72. A. Shabbir, A. Cox, L. Rodriguez-Menocal, M. Salgado, E. Van Badiavas, Mesenchymal stem cell exosomes induce proliferation and migration of normal and chronic wound fibroblasts, and enhance angiogenesis in vitro, Stem Cells Dev, 24 (2015) 1635-1647.
73. J. Jaussaud, M. Biais, J. Calderon, J. Chevaleyre, P. Duchez, Z. Ivanovic, T. Couffinhal, L. Barandon, Hypoxia-preconditioned mesenchymal stromal cells improve cardiac function in a swine model of chronic myocardial ischaemia, Eur J Cardiothorac Surg, 43 (2013) 1050-1057.
74. D. Chang, T. Fan, S. Gao, Y. Jin, M. Zhang, M. Ono, Application of mesenchymal stem cell sheet to treatment of ischemic heart disease, Stem Cell Res Ther, 12 (2021)
75. Y.L. Tang, W. Zhu, M. Cheng, L. Chen, J. Zhang, T. Sun, R. Kishore, M.I. Phillips, D.W. Losordo, G. Qin, Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing cxcr4 expression, Circ Res, 104 (2009) 1209-1216.
76. C. Bianco, C. Cotten, E. Lonardo, L. Strizzi, C. Baraty, M. Mancino, M. Gonzales, K. Watanabe, T. Nagaoka, C. Berry, A.E. Arai, G. Minchiotti, D.S. Salomon, Cripto-1 is required for hypoxia to induce cardiac differentiation of mouse embryonic stem cells, Am J Pathol, 175 (2009) 2146-2158.
77. T.L. Medley, M. Furtado, N.T. Lam, R. Idrizi, D. Williams, P.J. Verma, M. Costa, D.M. Kaye, Effect of oxygen on cardiac differentiation in mouse ips cells: Role of hypoxia inducible factor-1 and wnt/beta-catenin signaling, PLoS One, 8 (2013)
78. W.L. Grayson, F. Zhao, B. Bunnell, T. Ma, Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells, Biochem Biophys Res Commun, 358 (2007) 948-953.
79. C. Hu, L. Li, Preconditioning influences mesenchymal stem cell properties in vitro and in vivo, J Cell Mol Med, 22 (2018) 1428-1442.
80. H. Drolle, M. Wagner, J. Vasold, A. Kutt, C. Deniffel, K. Sotlar, S. Sironi, T. Herold, C. Rieger, M. Fiegl, Hypoxia regulates proliferation of acute myeloid leukemia and sensitivity against chemotherapy, Leuk Res, 39 (2015) 779-785.
81. C. Holzwarth, M. Vaegler, F. Gieseke, S.M. Pfister, R. Handgretinger, G. Kerst, I. Muller, Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells, BMC Cell Biol, 11 (2010)
82. M. Roemeling-van Rhijn, F.K. Mensah, S.S. Korevaar, M.J. Leijs, G.J. van Osch, J.N. Ijzermans, M.G. Betjes, C.C. Baan, W. Weimar, M.J. Hoogduijn, Effects of hypoxia on the immunomodulatory properties of adipose tissue-derived mesenchymal stem cells, Front Immunol, 4 (2013)
83. W. Zhu, J. Chen, X. Cong, S. Hu, X. Chen, Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells, Stem Cells, 24 (2006) 416-425.